Hepatocellular Carcinoma (Liver Cancer): Stages, Treatment, and When Transplant Is the Answer
Reviewed by Dr. Chetan Kalal, Hepatologist and Liver Transplant Physician, Mumbai. Last updated: August 2026. The short answer Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. In the large majority of patients it does not appear in a healthy liver — it grows inside a liver already damaged by cirrhosis, hepatitis B, hepatitis C, or fatty liver disease. That single fact governs everything that follows: treatment has to deal with two diseases at once, the tumour and the failing liver underneath it. Whether HCC is curable depends almost entirely on when it is found, not on how aggressive it looks. Found early, on a routine six-monthly scan in a patient known to have cirrhosis, it is often curable — by surgery, by ablation, or by liver transplant. Found late, when the patient first develops symptoms, the goal usually shifts from cure to control. If you or a family member has just been told there is a mass in the liver, the most useful thing you can do in the next week is get the case in front of a hepatologist or a liver multidisciplinary team before any treatment is started. Sequence matters enormously in this disease, and the first decision often closes or opens the door to a cure. Why liver cancer behaves differently from other cancers In most cancers, the organ around the tumour is healthy. Surgeons can remove a generous margin and the organ recovers. The liver is different. In HCC, the surrounding liver is usually cirrhotic — scarred, stiff, and working at reduced capacity. That creates two problems that shape every treatment decision: You cannot always remove the tumour safely. A cirrhotic liver may not have enough healthy reserve left to survive a large resection. A patient may have a technically removable tumour and still be inoperable, because the liver that remains would fail. The rest of the liver is also at risk. Cirrhosis is a field defect. Even after a tumour is perfectly removed, the remaining liver continues to generate new tumours. This is why recurrence rates after resection are high, and why transplant — which removes the whole diseased organ — occupies a unique place in liver cancer that it does not occupy in most other cancers. This is also the reason a liver cancer diagnosis should be managed by a team that includes a hepatologist, not by tumour-directed treatment alone. Assessing how much liver function is left is as important as measuring the tumour. Who is at risk, and who should be screened HCC is not a random event. It has a well-defined at-risk population, which is what makes screening possible. You are in the at-risk group if you have: Cirrhosis of any cause — alcohol-related, hepatitis B, hepatitis C, fatty liver disease (MASLD/MASH), autoimmune, or others Chronic hepatitis B infection, in whom liver cancer can develop even without cirrhosis — a pattern particularly relevant in India and much of Asia Advanced fibrosis from fatty liver disease, increasingly the fastest-growing risk group in Indian practice Prior hepatitis C that has been cured but had already caused cirrhosis — the risk falls after cure but does not fall to zero, and surveillance continues What screening actually is: an ultrasound of the abdomen every six months, usually with a blood test for alpha-fetoprotein (AFP). It is not expensive, it is not invasive, and it is the single intervention that most reliably converts an incurable liver cancer into a curable one. The uncomfortable reality in India is that most patients with HCC arrive at a specialist having never had a surveillance scan — often because nobody told them their fatty liver or their hepatitis B carried a cancer risk at all. If you have been told you have cirrhosis or chronic hepatitis B and you are not on a six-monthly scan, that is a gap worth closing this month. How liver cancer is diagnosed Liver cancer is one of the few solid tumours that can be confidently diagnosed without a biopsy. In a patient known to have cirrhosis, a lesion showing the characteristic blood-flow pattern on a multiphase CT or MRI — enhancing brightly in the arterial phase, then washing out in the later phases — is diagnostic of HCC in its own right. This matters practically. It means the diagnostic pathway is: Ultrasound picks up a suspicious lesion Triple-phase CT or MRI of the liver characterises it — this is the decisive test, and a plain CT scan is not adequate Blood tests — liver function, clotting, AFP, viral markers Endoscopy to look for varices, because portal hypertension changes what treatment is safe Staging scans to check for spread outside the liver Biopsy is reserved for cases where imaging is not conclusive, or where the liver is not cirrhotic and the diagnosis is genuinely in doubt. If you have been advised a biopsy before a proper multiphase scan has been done, ask why. Staging: what the stage actually determines Liver cancer is not staged the way most cancers are. The system used internationally — the Barcelona Clinic Liver Cancer (BCLC) system — combines three things: the tumour, the function of the liver, and how well the patient is functioning day to day. All three drive the treatment decision. Stage What it means Treatment usually considered Very early (0) A single small tumour, well-preserved liver function Ablation or surgical resection — potentially curative Early (A) Single tumour, or up to three small tumours; good liver function; patient fully active Resection, ablation, or liver transplant — potentially curative Intermediate (B) Multiple tumours confined to the liver, no vascular invasion or spread TACE or TARE (treatment delivered through the artery feeding the tumour); some patients can be downstaged toward transplant Advanced (C) Tumour invading blood vessels, or spread outside the liver Systemic therapy — modern immunotherapy-based combinations Terminal (D) Severely impaired liver function or very poor performance status Best supportive care; transplant assessment in highly selected cases Two people with identical-looking scans can end
